Phase II Trial of Gefitinib 250 mgDaily in Patientswith Recurrent and / orMetastatic Squamous Cell Carcinoma of the Head and Neck

@inproceedings{Cohen2005PhaseIT,
  title={Phase II Trial of Gefitinib 250 mgDaily in Patientswith Recurrent and / orMetastatic Squamous Cell Carcinoma of the Head and Neck},
  author={Ezra E. W. Cohen and MadeleineA. Kane and MarcyA. List and Bruce Earl Brockstein and BhoomiMehrotra and Dezheng Huo and AnnM. Mauer and Carolyn S Pierce and Allison Dekker and Everett E. Vokes},
  year={2005}
}
Purpose:Anobjective response rate of11%was reported in patients with recurrent and/ormetastatic squamous cell carcinomaof theheadandneck (SCCHN) treatedwith 500mgdaily gefitinib although the recommended dose in lung cancer is 250 mg.This study evaluated the efficacy and toxicity of 250mg daily gefitinib in patients with recurrent and/or metastatic SCCHN. Experimental Design:Phase II trialwithobjective response rate as theprimaryendpoint.Measurements of quality of life and levels of serum… CONTINUE READING